DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death

Launched by UNIVERSITY OF CAMPANIA LUIGI VANVITELLI · Mar 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Brugada syndrome, which can increase the risk of sudden cardiac death due to irregular heartbeats. The researchers want to find out if certain changes in a person’s DNA, specifically in a process called DNA methylation, can help distinguish between patients with Brugada syndrome and healthy individuals. They are also interested in seeing if these DNA changes can identify patients at high risk versus low risk for sudden cardiac death.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of Brugada syndrome, which is determined through specific heart test results. The study is open to both men and women, and it will not include patients who are related to one another or those who do not have the specific type of Brugada pattern needed for the trial. Although the study is not yet recruiting participants, those who join can expect to provide blood samples for analysis to help better understand the risks associated with this syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.
• • \>18 years
• • Unrelated patients
• Exclusion Criteria:
• • Related patients
• • Not type 1 Br patter